Rates for Anaphylaxis for Patients with Rheumatoid Arthritis Treated with Tocilizumab or Other Biologics: An Analysis Based on Health Claims Data

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/18901
• EU PAS number:
  EUPAS18844
• Study ID:
  18901
• Official title and acronym:
  Rates for Anaphylaxis for Patients with Rheumatoid Arthritis Treated with Tocilizumab or Other Biologics: An Analysis Based on Health Claims Data
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study status:
  Finalised

Research institution and networks

Institutions

F. Hoffmann-La Roche

Study timelines

Date when funding contract was signed

Actual: 15/11/2014

Study start date

Actual: 01/12/2014

Data analysis start date

Actual: 01/12/2014

Date of final study report

Actual: 03/12/2014

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

F. Hoffmann-La Roche Ltd

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)

Other study registration identification numbers and links

GA29837